

ASX Announcement

18 September 2023

Cleansing Notice Under Section 708A(5)(E) of the Corporations Act

Recce Pharmaceuticals Ltd (ASX:RCE) (**Company**) advises that it has today issued 18,181,819 fully paid ordinary shares (**New Shares**) in accordance with the Company's ASX announcement of 11 September 2023 regarding the Company successfully raising a total of \$8 million (before costs) in a placement to institutional, sophisticated and professional investors (**Placement**) by the issue of New Shares at the offer price of \$0.44 (44 cents) per New Share.

The Company gives this notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) and states the following:

1. the 18,181,819 New Shares issued in relation to the Placement were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b) section 674 of the Corporations Act;
3. as at the date of this notice, there is no excluded information for the purposes of sections 708A(7) and 708A(8) of the Corporations Act.

This announcement has been approved for release by the Board.

For more information, please contact:

James Graham
Chief Executive Officer
+61 2 9256 2571



ASX: RCE, FSE: R9Q

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 T +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA